Hormonal

Transitioning from dulaglutide to tirzepatide improves glycemic control (increased time in range, decreased mean glucose) without increasing hypoglycemia in patients with type 2 diabetes undergoing hemodialysis.

For patients with type 2 diabetes on hemodialysis who are not achieving good blood sugar control on dulaglutide, switching to tirzepatide (2.5 mg weekly) can significantly improve blood sugar stability and reduce high blood sugar episodes without increasing the risk of dangerous low blood sugar. This switch should be considered when current therapy fails, keeping in mind that mild stomach issues may occur but are generally manageable.